CanStaging+

Welcome to CanStaging+, developed by a collaboration between the Northern Ireland Cancer Registry (NICR), the International Agency for Research on Cancer (IARC), the Union for International Cancer Control (UICC) ), and Cancer Council Queensland (CCQ). The tool is designed to help maximise the availability, standardisation and comparability of cancer staging internationally. The tool provides automatic calculation of the international TNM staging classification versions 7 and 8 for a variety of tumour sites – breast, cervix, liver, lung, oesophagus, ovary, pancreas, prostate and stomach. Colorectal cancer may be staged using the TNM staging versions 5 and 8. The Tool also provides automatic calculation of stage for childhood cancers using the business rules developed for the Toronto Paediatric Cancer Stage Guidelines. In the future, the tool will be available in several languages.

For further information about the Staging Guidelines used in this tool, please refer to The Union for International Cancer Control (UICC) TNM Resources and for childhood staging the Toronto Paediatric Cancer Stage Guidelines.


Available staging systems:

Toronto Guidelines
Toronto Paediatric Cancer Staging Guidelines
Essential TNM
TNM edition 7
TNM edition 8

Endorsed by:


Used with the permission of the Union for International Cancer Control (UICC), Geneva, Switzerland. The original source for this materials are Leslie H. Sobin (Editor), Mary K. Gospodarowicz (Editor), Christian Wittekind (Editor), 'TNM Classification of Malignant Tumours, 7th Edition', published in 2009 by Wiley-Blackwell, James D. Brierley (Editor), Mary K. Gospodarowicz (Editor), Christian Wittekind (Editor), 'TNM Classification of Malignant Tumours, 8th Edition', published in 2016 by Wiley-Blackwell, and Piñeros M, Parkin DM, Ward K, Chokunonga E, Ervik M, Farrugia H, Gospodarowicz M, O'Sullivan B, Soerjomataram I, Swaminathan R, Znaor A, Bray F, Brierley J., 'Essential TNM: a registry tool to reduce gaps in cancer staging information', published in 2019 in Lancet Oncol. 20(2):e103-e111. doi:10.1016/S1470-2045(18)30897-0.

This tool has been partly funded by the International Cancer Benchmarking Partnership (ICBP) and has been reproduced with due care. Any inconsistencies with the UICC TNM classification 7th and 8th editions in addition to essential TNM and published errata are unintentional. Neither NICR, IARC nor UICC carry any liability should unforeseen errors emerge. However we would be pleased to receive all comments on any inconsistencies.